Masitinib	B:C2351398
for	O
treatment	O
of	O
severely	O
symptomatic	O
indolent	O
systemic	I:C0272203
mastocytosis	I:C0272203
:	O
a	O
randomised	O
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
,	O
phase	O
3	I:C0282461
study	I:C0282461
Indolent	O
systemic	I:C0272203
mastocytosis	I:C0272203
,	O
including	O
the	O
subvariant	O
of	O
smouldering	O
systemic	I:C3897042
mastocytosis	I:C3897042
,	O
is	O
a	O
lifelong	O
condition	O
associated	O
with	O
reduced	O
quality	I:C1963786
of	I:C1963786
life	I:C1963786
.	O

Masitinib	O
for	O
treatment	B:C0087111
of	O
severely	O
symptomatic	O
indolent	O
systemic	I:C0272203
mastocytosis	I:C0272203
:	O
a	O
randomised	O
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
,	O
phase	O
3	I:C0282461
study	I:C0282461
Indolent	O
systemic	I:C0272203
mastocytosis	I:C0272203
,	O
including	O
the	O
subvariant	O
of	O
smouldering	O
systemic	I:C3897042
mastocytosis	I:C3897042
,	O
is	O
a	O
lifelong	O
condition	O
associated	O
with	O
reduced	O
quality	I:C1963786
of	I:C1963786
life	I:C1963786
.	O

Masitinib	O
for	O
treatment	O
of	O
severely	O
symptomatic	O
indolent	B:C0272203
systemic	I:C0272203
mastocytosis	I:C0272203
:	O
a	O
randomised	O
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
,	O
phase	O
3	I:C0282461
study	I:C0282461
Indolent	O
systemic	I:C0272203
mastocytosis	I:C0272203
,	O
including	O
the	O
subvariant	O
of	O
smouldering	O
systemic	I:C3897042
mastocytosis	I:C3897042
,	O
is	O
a	O
lifelong	O
condition	O
associated	O
with	O
reduced	O
quality	I:C1963786
of	I:C1963786
life	I:C1963786
.	O

Masitinib	O
for	O
treatment	O
of	O
severely	O
symptomatic	O
indolent	O
systemic	I:C0272203
mastocytosis	I:C0272203
:	O
a	O
randomised	B:C0034656
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
,	O
phase	O
3	I:C0282461
study	I:C0282461
Indolent	O
systemic	I:C0272203
mastocytosis	I:C0272203
,	O
including	O
the	O
subvariant	O
of	O
smouldering	O
systemic	I:C3897042
mastocytosis	I:C3897042
,	O
is	O
a	O
lifelong	O
condition	O
associated	O
with	O
reduced	O
quality	I:C1963786
of	I:C1963786
life	I:C1963786
.	O

Masitinib	O
for	O
treatment	O
of	O
severely	O
symptomatic	O
indolent	O
systemic	I:C0272203
mastocytosis	I:C0272203
:	O
a	O
randomised	O
,	O
placebo	B:C1706408
-	I:C1706408
controlled	I:C1706408
,	O
phase	O
3	I:C0282461
study	I:C0282461
Indolent	O
systemic	I:C0272203
mastocytosis	I:C0272203
,	O
including	O
the	O
subvariant	O
of	O
smouldering	O
systemic	I:C3897042
mastocytosis	I:C3897042
,	O
is	O
a	O
lifelong	O
condition	O
associated	O
with	O
reduced	O
quality	I:C1963786
of	I:C1963786
life	I:C1963786
.	O

Masitinib	O
for	O
treatment	O
of	O
severely	O
symptomatic	O
indolent	O
systemic	I:C0272203
mastocytosis	I:C0272203
:	O
a	O
randomised	O
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
,	O
phase	B:C0282461
3	I:C0282461
study	I:C0282461
Indolent	O
systemic	I:C0272203
mastocytosis	I:C0272203
,	O
including	O
the	O
subvariant	O
of	O
smouldering	O
systemic	I:C3897042
mastocytosis	I:C3897042
,	O
is	O
a	O
lifelong	O
condition	O
associated	O
with	O
reduced	O
quality	I:C1963786
of	I:C1963786
life	I:C1963786
.	O

Masitinib	O
for	O
treatment	O
of	O
severely	O
symptomatic	O
indolent	O
systemic	I:C0272203
mastocytosis	I:C0272203
:	O
a	O
randomised	O
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
,	O
phase	O
3	I:C0282461
study	I:C0282461
Indolent	B:C0272203
systemic	I:C0272203
mastocytosis	I:C0272203
,	O
including	O
the	O
subvariant	O
of	O
smouldering	O
systemic	I:C3897042
mastocytosis	I:C3897042
,	O
is	O
a	O
lifelong	O
condition	O
associated	O
with	O
reduced	O
quality	I:C1963786
of	I:C1963786
life	I:C1963786
.	O

Masitinib	O
for	O
treatment	O
of	O
severely	O
symptomatic	O
indolent	O
systemic	I:C0272203
mastocytosis	I:C0272203
:	O
a	O
randomised	O
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
,	O
phase	O
3	I:C0282461
study	I:C0282461
Indolent	O
systemic	I:C0272203
mastocytosis	I:C0272203
,	O
including	O
the	O
subvariant	O
of	O
smouldering	B:C3897042
systemic	I:C3897042
mastocytosis	I:C3897042
,	O
is	O
a	O
lifelong	O
condition	O
associated	O
with	O
reduced	O
quality	I:C1963786
of	I:C1963786
life	I:C1963786
.	O

Masitinib	O
for	O
treatment	O
of	O
severely	O
symptomatic	O
indolent	O
systemic	I:C0272203
mastocytosis	I:C0272203
:	O
a	O
randomised	O
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
,	O
phase	O
3	I:C0282461
study	I:C0282461
Indolent	O
systemic	I:C0272203
mastocytosis	I:C0272203
,	O
including	O
the	O
subvariant	O
of	O
smouldering	O
systemic	I:C3897042
mastocytosis	I:C3897042
,	O
is	O
a	O
lifelong	O
condition	O
associated	O
with	O
reduced	B:C1963786
quality	I:C1963786
of	I:C1963786
life	I:C1963786
.	O

Masitinib	B:C2351398
inhibits	O
KIT	O
and	O
LYN	O
kinases	I:C1442804
that	O
are	O
involved	O
in	O
indolent	O
systemic	I:C0272203
mastocytosis	I:C0272203
pathogenesis	O
.	O

Masitinib	O
inhibits	O
KIT	B:C0033640
and	O
LYN	O
kinases	I:C1442804
that	O
are	O
involved	O
in	O
indolent	O
systemic	I:C0272203
mastocytosis	I:C0272203
pathogenesis	O
.	O

Masitinib	O
inhibits	O
KIT	O
and	O
LYN	B:C1442804
kinases	I:C1442804
that	O
are	O
involved	O
in	O
indolent	O
systemic	I:C0272203
mastocytosis	I:C0272203
pathogenesis	O
.	O

Masitinib	O
inhibits	O
KIT	O
and	O
LYN	O
kinases	I:C1442804
that	O
are	O
involved	O
in	O
indolent	B:C0272203
systemic	I:C0272203
mastocytosis	I:C0272203
pathogenesis	O
.	O

Masitinib	O
inhibits	O
KIT	O
and	O
LYN	O
kinases	I:C1442804
that	O
are	O
involved	O
in	O
indolent	O
systemic	I:C0272203
mastocytosis	I:C0272203
pathogenesis	B:C0699748
.	O

We	O
aimed	O
to	O
assess	O
safety	B:C1705187
and	O
efficacy	O
of	O
masitinib	O
versus	O
placebo	O
in	O
severely	O
symptomatic	I:C0436345
patients	O
who	O
were	O
unresponsive	O
to	O
optimal	O
symptomatic	O
treatments	O
.	O

We	O
aimed	O
to	O
assess	O
safety	O
and	O
efficacy	B:C1707887
of	O
masitinib	O
versus	O
placebo	O
in	O
severely	O
symptomatic	I:C0436345
patients	O
who	O
were	O
unresponsive	O
to	O
optimal	O
symptomatic	O
treatments	O
.	O

We	O
aimed	O
to	O
assess	O
safety	O
and	O
efficacy	O
of	O
masitinib	B:C2351398
versus	O
placebo	O
in	O
severely	O
symptomatic	I:C0436345
patients	O
who	O
were	O
unresponsive	O
to	O
optimal	O
symptomatic	O
treatments	O
.	O

We	O
aimed	O
to	O
assess	O
safety	O
and	O
efficacy	O
of	O
masitinib	O
versus	O
placebo	B:C1696465
in	O
severely	O
symptomatic	I:C0436345
patients	O
who	O
were	O
unresponsive	O
to	O
optimal	O
symptomatic	O
treatments	O
.	O

We	O
aimed	O
to	O
assess	O
safety	O
and	O
efficacy	O
of	O
masitinib	O
versus	O
placebo	O
in	O
severely	B:C0436345
symptomatic	I:C0436345
patients	O
who	O
were	O
unresponsive	O
to	O
optimal	O
symptomatic	O
treatments	O
.	O

We	O
aimed	O
to	O
assess	O
safety	O
and	O
efficacy	O
of	O
masitinib	O
versus	O
placebo	O
in	O
severely	O
symptomatic	I:C0436345
patients	O
who	O
were	O
unresponsive	O
to	O
optimal	O
symptomatic	O
treatments	B:C0087111
.	O

In	O
this	O
randomised	B:C0034656
,	O
double	O
-	I:C0013072
blind	I:C0013072
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
,	O
phase	O
3	I:C0282461
study	I:C0282461
,	O
we	O
enrolled	O
adults	O
(	O
aged	O
18	O
-	O
75	O
years	O
)	O
with	O
indolent	O
or	O
smouldering	O
systemic	I:C3897042
mastocytosis	I:C3897042
,	O
according	O
to	O
WHO	O
classification	O
or	O
documented	O
mastocytosis	O
based	O
on	O
histological	O
criteria	I:C0449574
,	O
at	O
50	O
centres	O
in	O
15	O
countries	O
.	O

In	O
this	O
randomised	O
,	O
double	B:C0013072
-	I:C0013072
blind	I:C0013072
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
,	O
phase	O
3	I:C0282461
study	I:C0282461
,	O
we	O
enrolled	O
adults	O
(	O
aged	O
18	O
-	O
75	O
years	O
)	O
with	O
indolent	O
or	O
smouldering	O
systemic	I:C3897042
mastocytosis	I:C3897042
,	O
according	O
to	O
WHO	O
classification	O
or	O
documented	O
mastocytosis	O
based	O
on	O
histological	O
criteria	I:C0449574
,	O
at	O
50	O
centres	O
in	O
15	O
countries	O
.	O

In	O
this	O
randomised	O
,	O
double	O
-	I:C0013072
blind	I:C0013072
,	O
placebo	B:C1706408
-	I:C1706408
controlled	I:C1706408
,	O
phase	O
3	I:C0282461
study	I:C0282461
,	O
we	O
enrolled	O
adults	O
(	O
aged	O
18	O
-	O
75	O
years	O
)	O
with	O
indolent	O
or	O
smouldering	O
systemic	I:C3897042
mastocytosis	I:C3897042
,	O
according	O
to	O
WHO	O
classification	O
or	O
documented	O
mastocytosis	O
based	O
on	O
histological	O
criteria	I:C0449574
,	O
at	O
50	O
centres	O
in	O
15	O
countries	O
.	O

In	O
this	O
randomised	O
,	O
double	O
-	I:C0013072
blind	I:C0013072
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
,	O
phase	B:C0282461
3	I:C0282461
study	I:C0282461
,	O
we	O
enrolled	O
adults	O
(	O
aged	O
18	O
-	O
75	O
years	O
)	O
with	O
indolent	O
or	O
smouldering	O
systemic	I:C3897042
mastocytosis	I:C3897042
,	O
according	O
to	O
WHO	O
classification	O
or	O
documented	O
mastocytosis	O
based	O
on	O
histological	O
criteria	I:C0449574
,	O
at	O
50	O
centres	O
in	O
15	O
countries	O
.	O

In	O
this	O
randomised	O
,	O
double	O
-	I:C0013072
blind	I:C0013072
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
,	O
phase	O
3	I:C0282461
study	I:C0282461
,	O
we	O
enrolled	O
adults	O
(	O
aged	O
18	O
-	O
75	O
years	O
)	O
with	O
indolent	B:C0272203
or	O
smouldering	O
systemic	I:C3897042
mastocytosis	I:C3897042
,	O
according	O
to	O
WHO	O
classification	O
or	O
documented	O
mastocytosis	O
based	O
on	O
histological	O
criteria	I:C0449574
,	O
at	O
50	O
centres	O
in	O
15	O
countries	O
.	O

In	O
this	O
randomised	O
,	O
double	O
-	I:C0013072
blind	I:C0013072
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
,	O
phase	O
3	I:C0282461
study	I:C0282461
,	O
we	O
enrolled	O
adults	O
(	O
aged	O
18	O
-	O
75	O
years	O
)	O
with	O
indolent	O
or	O
smouldering	B:C3897042
systemic	I:C3897042
mastocytosis	I:C3897042
,	O
according	O
to	O
WHO	O
classification	O
or	O
documented	O
mastocytosis	O
based	O
on	O
histological	O
criteria	I:C0449574
,	O
at	O
50	O
centres	O
in	O
15	O
countries	O
.	O

In	O
this	O
randomised	O
,	O
double	O
-	I:C0013072
blind	I:C0013072
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
,	O
phase	O
3	I:C0282461
study	I:C0282461
,	O
we	O
enrolled	O
adults	O
(	O
aged	O
18	O
-	O
75	O
years	O
)	O
with	O
indolent	O
or	O
smouldering	O
systemic	I:C3897042
mastocytosis	I:C3897042
,	O
according	O
to	O
WHO	B:C0043237
classification	O
or	O
documented	O
mastocytosis	O
based	O
on	O
histological	O
criteria	I:C0449574
,	O
at	O
50	O
centres	O
in	O
15	O
countries	O
.	O

In	O
this	O
randomised	O
,	O
double	O
-	I:C0013072
blind	I:C0013072
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
,	O
phase	O
3	I:C0282461
study	I:C0282461
,	O
we	O
enrolled	O
adults	O
(	O
aged	O
18	O
-	O
75	O
years	O
)	O
with	O
indolent	O
or	O
smouldering	O
systemic	I:C3897042
mastocytosis	I:C3897042
,	O
according	O
to	O
WHO	O
classification	B:C0008902
or	O
documented	O
mastocytosis	O
based	O
on	O
histological	O
criteria	I:C0449574
,	O
at	O
50	O
centres	O
in	O
15	O
countries	O
.	O

In	O
this	O
randomised	O
,	O
double	O
-	I:C0013072
blind	I:C0013072
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
,	O
phase	O
3	I:C0282461
study	I:C0282461
,	O
we	O
enrolled	O
adults	O
(	O
aged	O
18	O
-	O
75	O
years	O
)	O
with	O
indolent	O
or	O
smouldering	O
systemic	I:C3897042
mastocytosis	I:C3897042
,	O
according	O
to	O
WHO	O
classification	O
or	O
documented	B:C0920316
mastocytosis	O
based	O
on	O
histological	O
criteria	I:C0449574
,	O
at	O
50	O
centres	O
in	O
15	O
countries	O
.	O

In	O
this	O
randomised	O
,	O
double	O
-	I:C0013072
blind	I:C0013072
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
,	O
phase	O
3	I:C0282461
study	I:C0282461
,	O
we	O
enrolled	O
adults	O
(	O
aged	O
18	O
-	O
75	O
years	O
)	O
with	O
indolent	O
or	O
smouldering	O
systemic	I:C3897042
mastocytosis	I:C3897042
,	O
according	O
to	O
WHO	O
classification	O
or	O
documented	O
mastocytosis	B:C0024899
based	O
on	O
histological	O
criteria	I:C0449574
,	O
at	O
50	O
centres	O
in	O
15	O
countries	O
.	O

In	O
this	O
randomised	O
,	O
double	O
-	I:C0013072
blind	I:C0013072
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
,	O
phase	O
3	I:C0282461
study	I:C0282461
,	O
we	O
enrolled	O
adults	O
(	O
aged	O
18	O
-	O
75	O
years	O
)	O
with	O
indolent	O
or	O
smouldering	O
systemic	I:C3897042
mastocytosis	I:C3897042
,	O
according	O
to	O
WHO	O
classification	O
or	O
documented	O
mastocytosis	O
based	O
on	O
histological	B:C0449574
criteria	I:C0449574
,	O
at	O
50	O
centres	O
in	O
15	O
countries	O
.	O

In	O
this	O
randomised	O
,	O
double	O
-	I:C0013072
blind	I:C0013072
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
,	O
phase	O
3	I:C0282461
study	I:C0282461
,	O
we	O
enrolled	O
adults	O
(	O
aged	O
18	O
-	O
75	O
years	O
)	O
with	O
indolent	O
or	O
smouldering	O
systemic	I:C3897042
mastocytosis	I:C3897042
,	O
according	O
to	O
WHO	O
classification	O
or	O
documented	O
mastocytosis	O
based	O
on	O
histological	O
criteria	I:C0449574
,	O
at	O
50	O
centres	O
in	O
15	O
countries	B:C0454664
.	O

We	O
excluded	O
patients	O
with	O
cutaneous	B:C0221912
or	O
non-severe	O
systemic	O
mastocytosis	I:C0221013
after	O
a	O
protocol	O
amendment	I:C1507394
.	O

We	O
excluded	O
patients	O
with	O
cutaneous	O
or	O
non-severe	O
systemic	B:C0221013
mastocytosis	I:C0221013
after	O
a	O
protocol	O
amendment	I:C1507394
.	O

We	O
excluded	O
patients	O
with	O
cutaneous	O
or	O
non-severe	O
systemic	O
mastocytosis	I:C0221013
after	O
a	O
protocol	B:C1507394
amendment	I:C1507394
.	O

Patients	O
were	O
centrally	O
randomised	B:C0034656
(	O
1:1	O
)	O
to	O
receive	O
either	O
oral	O
masitinib	O
(	O
6	O
mg	O
/	O
kg	O
per	O
day	O
over	O
24	O
weeks	O
with	O
possible	O
extension	O
)	O
or	O
matched	O
placebo	O
with	O
minimisation	O
according	O
to	O
severe	O
symptoms	I:C0436345
.	O

Patients	O
were	O
centrally	O
randomised	O
(	O
1:1	O
)	O
to	O
receive	O
either	O
oral	O
masitinib	B:C2351398
(	O
6	O
mg	O
/	O
kg	O
per	O
day	O
over	O
24	O
weeks	O
with	O
possible	O
extension	O
)	O
or	O
matched	O
placebo	O
with	O
minimisation	O
according	O
to	O
severe	O
symptoms	I:C0436345
.	O

Patients	O
were	O
centrally	O
randomised	O
(	O
1:1	O
)	O
to	O
receive	O
either	O
oral	O
masitinib	O
(	O
6	O
mg	O
/	O
kg	O
per	O
day	O
over	O
24	O
weeks	O
with	O
possible	O
extension	O
)	O
or	O
matched	O
placebo	B:C1696465
with	O
minimisation	O
according	O
to	O
severe	O
symptoms	I:C0436345
.	O

Patients	O
were	O
centrally	O
randomised	O
(	O
1:1	O
)	O
to	O
receive	O
either	O
oral	O
masitinib	O
(	O
6	O
mg	O
/	O
kg	O
per	O
day	O
over	O
24	O
weeks	O
with	O
possible	O
extension	O
)	O
or	O
matched	O
placebo	O
with	O
minimisation	O
according	O
to	O
severe	B:C0436345
symptoms	I:C0436345
.	O

The	O
primary	B:C2986535
endpoint	I:C2986535
was	O
cumulative	O
response	O
(	O
≥75	O
%	O
improvement	O
from	O
baseline	O
within	O
weeks	O
8	O
-	O
24	O
)	O
in	O
at	O
least	O
one	O
severe	O
baseline	I:C0436345
symptom	I:C0436345
from	O
the	O
following	O
:	O
pruritus	O
score	O
of	O
9	O
or	O
more	O
,	O
eight	O
or	O
more	O
flushes	O
per	O
week	O
,	O
Hamilton	O
Rating	I:C0451203
Scale	I:C0451203
for	I:C0451203
Depression	I:C0451203
of	O
19	O
or	O
more	O
,	O
or	O
Fatigue	O
Impact	I:C2733557
Scale	I:C2733557
of	O
75	O
or	O
more	O
.	O

The	O
primary	O
endpoint	I:C2986535
was	O
cumulative	O
response	B:C0521982
(	O
≥75	O
%	O
improvement	O
from	O
baseline	O
within	O
weeks	O
8	O
-	O
24	O
)	O
in	O
at	O
least	O
one	O
severe	O
baseline	I:C0436345
symptom	I:C0436345
from	O
the	O
following	O
:	O
pruritus	O
score	O
of	O
9	O
or	O
more	O
,	O
eight	O
or	O
more	O
flushes	O
per	O
week	O
,	O
Hamilton	O
Rating	I:C0451203
Scale	I:C0451203
for	I:C0451203
Depression	I:C0451203
of	O
19	O
or	O
more	O
,	O
or	O
Fatigue	O
Impact	I:C2733557
Scale	I:C2733557
of	O
75	O
or	O
more	O
.	O

The	O
primary	O
endpoint	I:C2986535
was	O
cumulative	O
response	O
(	O
≥75	O
%	O
improvement	O
from	O
baseline	O
within	O
weeks	O
8	O
-	O
24	O
)	O
in	O
at	O
least	O
one	O
severe	B:C0436345
baseline	I:C0436345
symptom	I:C0436345
from	O
the	O
following	O
:	O
pruritus	O
score	O
of	O
9	O
or	O
more	O
,	O
eight	O
or	O
more	O
flushes	O
per	O
week	O
,	O
Hamilton	O
Rating	I:C0451203
Scale	I:C0451203
for	I:C0451203
Depression	I:C0451203
of	O
19	O
or	O
more	O
,	O
or	O
Fatigue	O
Impact	I:C2733557
Scale	I:C2733557
of	O
75	O
or	O
more	O
.	O

The	O
primary	O
endpoint	I:C2986535
was	O
cumulative	O
response	O
(	O
≥75	O
%	O
improvement	O
from	O
baseline	O
within	O
weeks	O
8	O
-	O
24	O
)	O
in	O
at	O
least	O
one	O
severe	O
baseline	I:C0436345
symptom	I:C0436345
from	O
the	O
following	O
:	O
pruritus	B:C0033774
score	O
of	O
9	O
or	O
more	O
,	O
eight	O
or	O
more	O
flushes	O
per	O
week	O
,	O
Hamilton	O
Rating	I:C0451203
Scale	I:C0451203
for	I:C0451203
Depression	I:C0451203
of	O
19	O
or	O
more	O
,	O
or	O
Fatigue	O
Impact	I:C2733557
Scale	I:C2733557
of	O
75	O
or	O
more	O
.	O

The	O
primary	O
endpoint	I:C2986535
was	O
cumulative	O
response	O
(	O
≥75	O
%	O
improvement	O
from	O
baseline	O
within	O
weeks	O
8	O
-	O
24	O
)	O
in	O
at	O
least	O
one	O
severe	O
baseline	I:C0436345
symptom	I:C0436345
from	O
the	O
following	O
:	O
pruritus	O
score	O
of	O
9	O
or	O
more	O
,	O
eight	O
or	O
more	O
flushes	O
per	O
week	O
,	O
Hamilton	B:C0451203
Rating	I:C0451203
Scale	I:C0451203
for	I:C0451203
Depression	I:C0451203
of	O
19	O
or	O
more	O
,	O
or	O
Fatigue	O
Impact	I:C2733557
Scale	I:C2733557
of	O
75	O
or	O
more	O
.	O

The	O
primary	O
endpoint	I:C2986535
was	O
cumulative	O
response	O
(	O
≥75	O
%	O
improvement	O
from	O
baseline	O
within	O
weeks	O
8	O
-	O
24	O
)	O
in	O
at	O
least	O
one	O
severe	O
baseline	I:C0436345
symptom	I:C0436345
from	O
the	O
following	O
:	O
pruritus	O
score	O
of	O
9	O
or	O
more	O
,	O
eight	O
or	O
more	O
flushes	O
per	O
week	O
,	O
Hamilton	O
Rating	I:C0451203
Scale	I:C0451203
for	I:C0451203
Depression	I:C0451203
of	O
19	O
or	O
more	O
,	O
or	O
Fatigue	B:C2733557
Impact	I:C2733557
Scale	I:C2733557
of	O
75	O
or	O
more	O
.	O

We	O
assessed	O
treatment	O
effect	O
using	O
repeated	O
measures	O
methodology	B:C0086912
for	O
rare	O
diseases	I:C0678236
via	O
the	O
generalised	O
estimating	I:C0282574
equation	I:C0282574
model	I:C0282574
in	O
a	O
modified	O
intention	O
-	I:C2718028
to	I:C2718028
-	I:C2718028
treat	I:C2718028
population	O
,	O
including	O
all	O
participants	O
assigned	O
to	O
treatment	O
minus	O
those	O
who	O
withdrew	O
due	O
to	O
a	O
non-treatment	O
-	I:C0243095
related	I:C0243095
cause	I:C0243095
.	O

We	O
assessed	O
treatment	O
effect	O
using	O
repeated	O
measures	O
methodology	O
for	O
rare	B:C0678236
diseases	I:C0678236
via	O
the	O
generalised	O
estimating	I:C0282574
equation	I:C0282574
model	I:C0282574
in	O
a	O
modified	O
intention	O
-	I:C2718028
to	I:C2718028
-	I:C2718028
treat	I:C2718028
population	O
,	O
including	O
all	O
participants	O
assigned	O
to	O
treatment	O
minus	O
those	O
who	O
withdrew	O
due	O
to	O
a	O
non-treatment	O
-	I:C0243095
related	I:C0243095
cause	I:C0243095
.	O

We	O
assessed	O
treatment	O
effect	O
using	O
repeated	O
measures	O
methodology	O
for	O
rare	O
diseases	I:C0678236
via	O
the	O
generalised	B:C0282574
estimating	I:C0282574
equation	I:C0282574
model	I:C0282574
in	O
a	O
modified	O
intention	O
-	I:C2718028
to	I:C2718028
-	I:C2718028
treat	I:C2718028
population	O
,	O
including	O
all	O
participants	O
assigned	O
to	O
treatment	O
minus	O
those	O
who	O
withdrew	O
due	O
to	O
a	O
non-treatment	O
-	I:C0243095
related	I:C0243095
cause	I:C0243095
.	O

We	O
assessed	O
treatment	O
effect	O
using	O
repeated	O
measures	O
methodology	O
for	O
rare	O
diseases	I:C0678236
via	O
the	O
generalised	O
estimating	I:C0282574
equation	I:C0282574
model	I:C0282574
in	O
a	O
modified	O
intention	B:C2718028
-	I:C2718028
to	I:C2718028
-	I:C2718028
treat	I:C2718028
population	O
,	O
including	O
all	O
participants	O
assigned	O
to	O
treatment	O
minus	O
those	O
who	O
withdrew	O
due	O
to	O
a	O
non-treatment	O
-	I:C0243095
related	I:C0243095
cause	I:C0243095
.	O

We	O
assessed	O
treatment	O
effect	O
using	O
repeated	O
measures	O
methodology	O
for	O
rare	O
diseases	I:C0678236
via	O
the	O
generalised	O
estimating	I:C0282574
equation	I:C0282574
model	I:C0282574
in	O
a	O
modified	O
intention	O
-	I:C2718028
to	I:C2718028
-	I:C2718028
treat	I:C2718028
population	B:C1257890
,	O
including	O
all	O
participants	O
assigned	O
to	O
treatment	O
minus	O
those	O
who	O
withdrew	O
due	O
to	O
a	O
non-treatment	O
-	I:C0243095
related	I:C0243095
cause	I:C0243095
.	O

We	O
assessed	O
treatment	O
effect	O
using	O
repeated	O
measures	O
methodology	O
for	O
rare	O
diseases	I:C0678236
via	O
the	O
generalised	O
estimating	I:C0282574
equation	I:C0282574
model	I:C0282574
in	O
a	O
modified	O
intention	O
-	I:C2718028
to	I:C2718028
-	I:C2718028
treat	I:C2718028
population	O
,	O
including	O
all	O
participants	B:C0679646
assigned	O
to	O
treatment	O
minus	O
those	O
who	O
withdrew	O
due	O
to	O
a	O
non-treatment	O
-	I:C0243095
related	I:C0243095
cause	I:C0243095
.	O

We	O
assessed	O
treatment	O
effect	O
using	O
repeated	O
measures	O
methodology	O
for	O
rare	O
diseases	I:C0678236
via	O
the	O
generalised	O
estimating	I:C0282574
equation	I:C0282574
model	I:C0282574
in	O
a	O
modified	O
intention	O
-	I:C2718028
to	I:C2718028
-	I:C2718028
treat	I:C2718028
population	O
,	O
including	O
all	O
participants	O
assigned	O
to	O
treatment	B:C0087111
minus	O
those	O
who	O
withdrew	O
due	O
to	O
a	O
non-treatment	O
-	I:C0243095
related	I:C0243095
cause	I:C0243095
.	O

We	O
assessed	O
treatment	O
effect	O
using	O
repeated	O
measures	O
methodology	O
for	O
rare	O
diseases	I:C0678236
via	O
the	O
generalised	O
estimating	I:C0282574
equation	I:C0282574
model	I:C0282574
in	O
a	O
modified	O
intention	O
-	I:C2718028
to	I:C2718028
-	I:C2718028
treat	I:C2718028
population	O
,	O
including	O
all	O
participants	O
assigned	O
to	O
treatment	O
minus	O
those	O
who	O
withdrew	O
due	O
to	O
a	O
non-treatment	B:C0243095
-	I:C0243095
related	I:C0243095
cause	I:C0243095
.	O

We	O
assessed	O
safety	B:C1705187
in	O
all	O
patients	O
who	O
received	O
at	O
least	O
one	O
dose	O
of	O
study	O
drug	I:C0013175
.	O

We	O
assessed	O
safety	O
in	O
all	O
patients	O
who	O
received	O
at	O
least	O
one	O
dose	O
of	O
study	B:C0013175
drug	I:C0013175
.	O

This	O
trial	B:C0008976
is	O
registered	O
with	O
ClinicalTrials.gov	O
,	I:C0008976
number	I:C0008976
NCT00814073	I:C0008976
.	O

This	O
trial	O
is	O
registered	O
with	O
ClinicalTrials.gov	B:C0008976
,	I:C0008976
number	I:C0008976
NCT00814073	I:C0008976
.	O

Between	O
Feb	O
19	O
,	O
2009	O
,	O
and	O
July	O
15	O
,	O
2015	O
,	O
135	O
patients	O
were	O
randomly	O
assigned	O
to	O
masitinib	B:C2351398
(	O
n=71	O
)	O
or	O
placebo	O
(	O
n=64	O
)	O
.	O

Between	O
Feb	O
19	O
,	O
2009	O
,	O
and	O
July	O
15	O
,	O
2015	O
,	O
135	O
patients	O
were	O
randomly	O
assigned	O
to	O
masitinib	O
(	O
n=71	O
)	O
or	O
placebo	B:C1696465
(	O
n=64	O
)	O
.	O

By	O
24	O
weeks	O
,	O
masitinib	B:C2351398
was	O
associated	O
with	O
a	O
cumulative	O
response	O
of	O
18·7	O
%	O
in	O
the	O
primary	O
endpoint	I:C2986535
(	O
122·6	O
responses	O
of	O
656·5	O
possible	O
responses	O
[	O
weighted	O
generalised	O
estimating	O
equation	O
]	O
)	O
compared	O
with	O
7·4	O
%	O
for	O
placebo	O
(	O
48·9	O
of	O
656·5	O
;	O
difference	O
11·3	O
%	O
;	O
odds	O
ratio	O
3·6	O
;	O
95	O
%	O
CI	O
1·2-10·8	O
;	O
p=0·0076	O
)	O
.	O

By	O
24	O
weeks	O
,	O
masitinib	O
was	O
associated	O
with	O
a	O
cumulative	O
response	B:C0521982
of	O
18·7	O
%	O
in	O
the	O
primary	O
endpoint	I:C2986535
(	O
122·6	O
responses	O
of	O
656·5	O
possible	O
responses	O
[	O
weighted	O
generalised	O
estimating	O
equation	O
]	O
)	O
compared	O
with	O
7·4	O
%	O
for	O
placebo	O
(	O
48·9	O
of	O
656·5	O
;	O
difference	O
11·3	O
%	O
;	O
odds	O
ratio	O
3·6	O
;	O
95	O
%	O
CI	O
1·2-10·8	O
;	O
p=0·0076	O
)	O
.	O

By	O
24	O
weeks	O
,	O
masitinib	O
was	O
associated	O
with	O
a	O
cumulative	O
response	O
of	O
18·7	O
%	O
in	O
the	O
primary	B:C2986535
endpoint	I:C2986535
(	O
122·6	O
responses	O
of	O
656·5	O
possible	O
responses	O
[	O
weighted	O
generalised	O
estimating	O
equation	O
]	O
)	O
compared	O
with	O
7·4	O
%	O
for	O
placebo	O
(	O
48·9	O
of	O
656·5	O
;	O
difference	O
11·3	O
%	O
;	O
odds	O
ratio	O
3·6	O
;	O
95	O
%	O
CI	O
1·2-10·8	O
;	O
p=0·0076	O
)	O
.	O

By	O
24	O
weeks	O
,	O
masitinib	O
was	O
associated	O
with	O
a	O
cumulative	O
response	O
of	O
18·7	O
%	O
in	O
the	O
primary	O
endpoint	I:C2986535
(	O
122·6	O
responses	B:C0521982
of	O
656·5	O
possible	O
responses	O
[	O
weighted	O
generalised	O
estimating	O
equation	O
]	O
)	O
compared	O
with	O
7·4	O
%	O
for	O
placebo	O
(	O
48·9	O
of	O
656·5	O
;	O
difference	O
11·3	O
%	O
;	O
odds	O
ratio	O
3·6	O
;	O
95	O
%	O
CI	O
1·2-10·8	O
;	O
p=0·0076	O
)	O
.	O

By	O
24	O
weeks	O
,	O
masitinib	O
was	O
associated	O
with	O
a	O
cumulative	O
response	O
of	O
18·7	O
%	O
in	O
the	O
primary	O
endpoint	I:C2986535
(	O
122·6	O
responses	O
of	O
656·5	O
possible	O
responses	B:C0521982
[	O
weighted	O
generalised	O
estimating	O
equation	O
]	O
)	O
compared	O
with	O
7·4	O
%	O
for	O
placebo	O
(	O
48·9	O
of	O
656·5	O
;	O
difference	O
11·3	O
%	O
;	O
odds	O
ratio	O
3·6	O
;	O
95	O
%	O
CI	O
1·2-10·8	O
;	O
p=0·0076	O
)	O
.	O

By	O
24	O
weeks	O
,	O
masitinib	O
was	O
associated	O
with	O
a	O
cumulative	O
response	O
of	O
18·7	O
%	O
in	O
the	O
primary	O
endpoint	I:C2986535
(	O
122·6	O
responses	O
of	O
656·5	O
possible	O
responses	O
[	O
weighted	O
generalised	O
estimating	O
equation	O
]	O
)	O
compared	O
with	O
7·4	O
%	O
for	O
placebo	B:C1696465
(	O
48·9	O
of	O
656·5	O
;	O
difference	O
11·3	O
%	O
;	O
odds	O
ratio	O
3·6	O
;	O
95	O
%	O
CI	O
1·2-10·8	O
;	O
p=0·0076	O
)	O
.	O

Frequent	O
severe	B:C1519255
adverse	I:C1519255
events	I:C1519255
(	O
>	O
4	O
%	O
difference	O
from	O
placebo	O
)	O
were	O
diarrhoea	O
(	O
eight	O
[	O
11	O
%	O
]	O
of	O
70	O
in	O
the	O
masitinib	O
group	O
vs	O
one	O
[	O
2	O
%	O
]	O
of	O
63	O
in	O
the	O
placebo	O
group	O
)	O
,	O
rash	O
(	O
four	O
[	O
6	O
%	O
]	O
vs	O
none	O
)	O
,	O
and	O
asthenia	O
(	O
four	O
[	O
6	O
%	O
]	O
vs	O
one	O
[	O
2	O
%	O
]	O
)	O
.	O

Frequent	O
severe	O
adverse	I:C1519255
events	I:C1519255
(	O
>	O
4	O
%	O
difference	O
from	O
placebo	B:C1696465
)	O
were	O
diarrhoea	O
(	O
eight	O
[	O
11	O
%	O
]	O
of	O
70	O
in	O
the	O
masitinib	O
group	O
vs	O
one	O
[	O
2	O
%	O
]	O
of	O
63	O
in	O
the	O
placebo	O
group	O
)	O
,	O
rash	O
(	O
four	O
[	O
6	O
%	O
]	O
vs	O
none	O
)	O
,	O
and	O
asthenia	O
(	O
four	O
[	O
6	O
%	O
]	O
vs	O
one	O
[	O
2	O
%	O
]	O
)	O
.	O

Frequent	O
severe	O
adverse	I:C1519255
events	I:C1519255
(	O
>	O
4	O
%	O
difference	O
from	O
placebo	O
)	O
were	O
diarrhoea	B:C0011991
(	O
eight	O
[	O
11	O
%	O
]	O
of	O
70	O
in	O
the	O
masitinib	O
group	O
vs	O
one	O
[	O
2	O
%	O
]	O
of	O
63	O
in	O
the	O
placebo	O
group	O
)	O
,	O
rash	O
(	O
four	O
[	O
6	O
%	O
]	O
vs	O
none	O
)	O
,	O
and	O
asthenia	O
(	O
four	O
[	O
6	O
%	O
]	O
vs	O
one	O
[	O
2	O
%	O
]	O
)	O
.	O

Frequent	O
severe	O
adverse	I:C1519255
events	I:C1519255
(	O
>	O
4	O
%	O
difference	O
from	O
placebo	O
)	O
were	O
diarrhoea	O
(	O
eight	O
[	O
11	O
%	O
]	O
of	O
70	O
in	O
the	O
masitinib	B:C2351398
group	O
vs	O
one	O
[	O
2	O
%	O
]	O
of	O
63	O
in	O
the	O
placebo	O
group	O
)	O
,	O
rash	O
(	O
four	O
[	O
6	O
%	O
]	O
vs	O
none	O
)	O
,	O
and	O
asthenia	O
(	O
four	O
[	O
6	O
%	O
]	O
vs	O
one	O
[	O
2	O
%	O
]	O
)	O
.	O

Frequent	O
severe	O
adverse	I:C1519255
events	I:C1519255
(	O
>	O
4	O
%	O
difference	O
from	O
placebo	O
)	O
were	O
diarrhoea	O
(	O
eight	O
[	O
11	O
%	O
]	O
of	O
70	O
in	O
the	O
masitinib	O
group	O
vs	O
one	O
[	O
2	O
%	O
]	O
of	O
63	O
in	O
the	O
placebo	B:C1696465
group	O
)	O
,	O
rash	O
(	O
four	O
[	O
6	O
%	O
]	O
vs	O
none	O
)	O
,	O
and	O
asthenia	O
(	O
four	O
[	O
6	O
%	O
]	O
vs	O
one	O
[	O
2	O
%	O
]	O
)	O
.	O

Frequent	O
severe	O
adverse	I:C1519255
events	I:C1519255
(	O
>	O
4	O
%	O
difference	O
from	O
placebo	O
)	O
were	O
diarrhoea	O
(	O
eight	O
[	O
11	O
%	O
]	O
of	O
70	O
in	O
the	O
masitinib	O
group	O
vs	O
one	O
[	O
2	O
%	O
]	O
of	O
63	O
in	O
the	O
placebo	O
group	O
)	O
,	O
rash	O
(	O
four	O
[	O
6	O
%	O
]	O
vs	O
none	O
)	O
,	O
and	O
asthenia	B:C0004093
(	O
four	O
[	O
6	O
%	O
]	O
vs	O
one	O
[	O
2	O
%	O
]	O
)	O
.	O

The	O
most	O
frequent	O
serious	B:C1519255
adverse	I:C1519255
events	I:C1519255
were	O
diarrhoea	O
(	O
three	O
patients	O
[	O
4	O
%	O
]	O
vs	O
one	O
[	O
2	O
%	O
]	O
)	O
and	O
urticaria	O
(	O
two	O
[	O
3	O
%	O
]	O
vs	O
none	O
)	O
,	O
and	O
no	O
life	O
-	I:C2826244
threatening	I:C2826244
toxicities	O
occurred	O
.	O

The	O
most	O
frequent	O
serious	O
adverse	I:C1519255
events	I:C1519255
were	O
diarrhoea	B:C0011991
(	O
three	O
patients	O
[	O
4	O
%	O
]	O
vs	O
one	O
[	O
2	O
%	O
]	O
)	O
and	O
urticaria	O
(	O
two	O
[	O
3	O
%	O
]	O
vs	O
none	O
)	O
,	O
and	O
no	O
life	O
-	I:C2826244
threatening	I:C2826244
toxicities	O
occurred	O
.	O

The	O
most	O
frequent	O
serious	O
adverse	I:C1519255
events	I:C1519255
were	O
diarrhoea	O
(	O
three	O
patients	O
[	O
4	O
%	O
]	O
vs	O
one	O
[	O
2	O
%	O
]	O
)	O
and	O
urticaria	B:C0042109
(	O
two	O
[	O
3	O
%	O
]	O
vs	O
none	O
)	O
,	O
and	O
no	O
life	O
-	I:C2826244
threatening	I:C2826244
toxicities	O
occurred	O
.	O

The	O
most	O
frequent	O
serious	O
adverse	I:C1519255
events	I:C1519255
were	O
diarrhoea	O
(	O
three	O
patients	O
[	O
4	O
%	O
]	O
vs	O
one	O
[	O
2	O
%	O
]	O
)	O
and	O
urticaria	O
(	O
two	O
[	O
3	O
%	O
]	O
vs	O
none	O
)	O
,	O
and	O
no	O
life	B:C2826244
-	I:C2826244
threatening	I:C2826244
toxicities	O
occurred	O
.	O

The	O
most	O
frequent	O
serious	O
adverse	I:C1519255
events	I:C1519255
were	O
diarrhoea	O
(	O
three	O
patients	O
[	O
4	O
%	O
]	O
vs	O
one	O
[	O
2	O
%	O
]	O
)	O
and	O
urticaria	O
(	O
two	O
[	O
3	O
%	O
]	O
vs	O
none	O
)	O
,	O
and	O
no	O
life	O
-	I:C2826244
threatening	I:C2826244
toxicities	B:C0600688
occurred	O
.	O

One	O
patient	O
in	O
the	O
placebo	B:C1696465
group	O
died	O
(	O
unrelated	O
to	O
study	O
treatment	I:C3161471
)	O
.	O

One	O
patient	O
in	O
the	O
placebo	O
group	O
died	B:C1546956
(	O
unrelated	O
to	O
study	O
treatment	I:C3161471
)	O
.	O

One	O
patient	O
in	O
the	O
placebo	O
group	O
died	O
(	O
unrelated	O
to	O
study	B:C3161471
treatment	I:C3161471
)	O
.	O

These	O
study	O
findings	O
indicate	O
that	O
masitinib	B:C2351398
is	O
an	O
effective	O
and	O
well	O
tolerated	O
agent	I:C1254351
for	O
the	O
treatment	O
of	O
severely	O
symptomatic	I:C0436345
indolent	O
or	O
smouldering	O
systemic	I:C3897042
mastocytosis	I:C3897042
.	O

These	O
study	O
findings	O
indicate	O
that	O
masitinib	O
is	O
an	O
effective	O
and	O
well	O
tolerated	B:C1254351
agent	I:C1254351
for	O
the	O
treatment	O
of	O
severely	O
symptomatic	I:C0436345
indolent	O
or	O
smouldering	O
systemic	I:C3897042
mastocytosis	I:C3897042
.	O

These	O
study	O
findings	O
indicate	O
that	O
masitinib	O
is	O
an	O
effective	O
and	O
well	O
tolerated	O
agent	I:C1254351
for	O
the	O
treatment	B:C0087111
of	O
severely	O
symptomatic	I:C0436345
indolent	O
or	O
smouldering	O
systemic	I:C3897042
mastocytosis	I:C3897042
.	O

These	O
study	O
findings	O
indicate	O
that	O
masitinib	O
is	O
an	O
effective	O
and	O
well	O
tolerated	O
agent	I:C1254351
for	O
the	O
treatment	O
of	O
severely	B:C0436345
symptomatic	I:C0436345
indolent	O
or	O
smouldering	O
systemic	I:C3897042
mastocytosis	I:C3897042
.	O

These	O
study	O
findings	O
indicate	O
that	O
masitinib	O
is	O
an	O
effective	O
and	O
well	O
tolerated	O
agent	I:C1254351
for	O
the	O
treatment	O
of	O
severely	O
symptomatic	I:C0436345
indolent	B:C0272203
or	O
smouldering	O
systemic	I:C3897042
mastocytosis	I:C3897042
.	O

These	O
study	O
findings	O
indicate	O
that	O
masitinib	O
is	O
an	O
effective	O
and	O
well	O
tolerated	O
agent	I:C1254351
for	O
the	O
treatment	O
of	O
severely	O
symptomatic	I:C0436345
indolent	O
or	O
smouldering	B:C3897042
systemic	I:C3897042
mastocytosis	I:C3897042
.	O

